anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: biotechnology.SUBSTANCE: invention relates to medical biotechnology. Described is a preparation α-antitrypsin, stimulating formation of reticulocytes, where said preparation α-antitrypsin contains peptide fragments as components, characterized by that said peptide fragments are fragments of a precursor α-antitrypsin, where said precursor α-antitrypsin has 418 amino acid residues. This factor can be separated and purified from the admixtures of the preparation α-antitrypsin (from human plasma), wherein it has been found to be a fragment of an antitrypsin precursor and has a very high ability to stimulate generation of reticulocytes in mice. Anti-EPO monoclonal antibody does not bind to the reticulocyte growth factor, which is labeled I, after binding of the growth factor of reticulocytes with surface receptors of bone marrow cells of mice, EPO can not compete with a growth factor of reticulocytes. EPO and RGF are labeled with different fluorochromes, and it is proved that they have different receptors. Factor of the present invention and EPO are introduced by injection into mice or mice with aplastic anemia, and a reliable synergetic effect of stimulating generation of reticulocytes, red blood cells and leukocytes is observed.EFFECT: growth factor of reticulocytes under the present invention can be used for preparing a drug for treating severe anemia.3 cl, 3 dwg, 6 tbl
PURPOSE: A facial cosmetic mask sheet pack of hybrid functioned red clay is provided to increase stability of cosmetic compositions for moisturizing effect, whitening, nutrient, appeasement, moisturizing, and skin regenerating effect, to increase an adhesive force to skin, and to continuously absorb the cosmetic compositions to the skin without skin irritation. CONSTITUTION: A facial cosmetic mask sheet pack of hybrid functioned red clay is manufactured by the following steps. 15%(weight ratio) of a dock pulp paper liquid of pounded fiber, 15%(weight ratio) of a jade powder that is finely ground to 300 mesh, 15%(weight ratio) of a biotite powder, and 35%(weight ratio) of red clay deposit are mixed to form a paper mixture, and the paper mixture is pounded; 10%(weight ratio) of rosin based on a total weight of the mixture is added as a surface agent and then coherently precipitated for 5 hours. Then, the mixture is initially formed as a paper and dried to form micropores in the functional material to the paper material in a paper machine. The paper is cut to cover the whole face as an environment-friendly pressed paper of a thin layer added with a function of Korean traditional paper while maintaining an effective active function of red clay, jade, and biotite that are far-infrared ray radiators. The mask can comprehensively satisfy moisturizing and nourishing properties required for a facial cosmetic pack mask, transferability for delivering cosmetic components through skin, adhering property for attaching the pack composition in an immersed state directly to the face of a user, and whitening property for whitening the skin with one mask pack.
Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from  Garcinia esculenta  or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
The present invention relates to a medical preparation product with botanical Chinese herbal medicines as main components, which is mainly used for curing a scald and a burn. The present invention particularly relates to a scald and burn medicine spraying agent and a preparation method thereof. The scald and burn medicine spraying agent of the present invention is composed of raw materials having the following weight portions of 1000 portions of spine date bark, and 8 to 16 portions of scutellaria, phellodendron, rehmannia roots, giant knotweed rhizome, alkanna tinctoria and angelica, and furthermore, the concentration of alcohol is from 20 % to 55 %. The preparation method of the present invention comprises that the raw materials are cut and soaked by the alcohol; the soaking solution is filtered to prepare the liquid product. The scald and burn medicine spraying agent of the present invention has good pharmacological action, such as pain stop, hemostasis, inflammation elimination, infection resistance, tissue regeneration, etc., enhances the action of disinfection and sterilization for the wound surface of patients, accelerates the healing of the wound surface and obviously shortens the curing time. Because the scald and burn medicine spraying agent of the present invention can be directly made into a spraying agent to spray the wound surface, no friction phenomenon for the wound surface occurs, the pain feeling for patients is obviously lightened, and no scars or few scars are remained after healing. The scald and burn medicine spraying agent of the present invention is extremely convenient in use.
The present invention relates generally to a method for the in vitro or in vivo production, by a eukaryotic host cell, of a protein from a negative sense single stranded RNA virus and, more particularly, to a method for the in vitro or in vivo production by a eukaryotic host cell of a protein from a virus of the family Paramyxoviradae and agents identified thereby. Still more particularly, said protein is the F, N, P or SH protein, the encoding nucleic acid molecule of which has been optimised for expression in a eukaryotic host cell. In yet another aspect, the present invention relates to a method for modulating the functional activity of an F protein. More particularly, said modulation is predicated on modulation of the functioning of a novel intrasequence cleavage event. In still another aspect, the protein expression product produced in accordance with the optimised expression method of the present invention and the method of modulating F protein functional activity are useful in a range of applications including, but not limited to, the identification, design and/or modification of agents capable of modulating functional activity of the subject protein. The proteins, encoding nucleic acid molecules and agents identified in accordance with the present invention are useful, inter alia, in the treatment and/or prophylaxis of viral infections.
The invention relates to a Chinese medicinal composition for promoting layers to lay eggs and a preparation method thereof. The Chinese medicinal composition is characterized by comprising the following medicaments in part by weight: 31 to 35 parts of Chinese angelica, 31 to 35 parts of cinnamomvine, and 31 to 35 parts of tangerine peel. The preparation method comprises the following steps of: proportioning the Chinese angelica, the cinnamomvine and the tangerine peel serving as raw materials, smashing and sieving the raw materials to reach the grain size of 60 to 200 meshes, and packing to obtain finished products. The Chinese medicinal composition has the advantage that the traditional Chinese medicines together have effects of tonifying and regulating vital energy, nourishing blood and promoting digestion so as to promote the layers to lay the eggs. The composition can improve the egg laying rate of the layers and prolong peak egg laying time, is quickly absorbed and convenient to use, has a high safety factor, and does not have any medicament residue or toxic or side effect. On the one hand, the medicines in the prescription are naturally obtained, are convenient to take and use and easy to prepare, and have low cost and a scientific using method; and on the other hand, medicament resistance cannot be generated, and particularly residue cannot be left in the bodies of hens after the composition is taken, so that the safety of people in eating the eggs and egg products can be effectively ensured.
FIELD: medicine; thermals methods for treating various diseases of human beings by artificially rising body temperature above 43 C. SUBSTANCE: patient is narcotized, followed by processing to preparatory operations preceding warming-up procedure. For this purpose the following medicaments are administered to patient in succession: pyridoxine is injected intravenously dropwise in a dose 5-8 mg/kg of body weight, 40-% hexamethylene tetramine solution, intravenously drop or jetwise in a dose 0.1 ml/kg of body weight, and oily alpha-tocopherol solution, subcutaneously in a dose 10 mg/ml of body weight. Before injection, 40-% hexamethyleme tetramine solution is diluted with 5-% glucose solution containing 30-40 mmoles of potassium chloride. Warming-up of patient's body is effected in hot water with temperature 44-46 C. Before plunging the patient into water, patient is narcotized deeper by administering sodium hydroxybutyrate in a dose 100-200 mg/kg of body weight. In addition, in process of warming-up procedure, hexamethylene tetramine is administered to patient intravenously drop- or jetwise in the form of 40-% solution diluted with 5-% glucose solution in a dose 0.1 mg/kg of body weight. EFFECT: new effective method for thermal therapy. 6 cl
Severe vision impairment and blindness in childhood have a significant health burden on the child, family and society. This review article seeks to provide a structured framework for managing the apparently blind child presenting in the first year of life, starting from a comprehensive history and examination. Different investigation modalities and the increasingly important role of genetics will also be described, in addition to common causes of severe vision impairment. Crucially, a systematic approach to the blind infant is key to correct diagnoses and timely management. Incorrect diagnoses can be costly to all involved, however it is important to note that diagnoses can change with ongoing follow-up and investigations. Furthermore, the modern age of ophthalmology requires a multi-disciplinary approach and close collaboration with specialists including paediatricians, neurologists and geneticists, in addition to rehabilitation and low vision services, to ensure the best care for these vulnerable infants.
The present invention belongs to the technical field of medicine, particularly to a pure Chinese herb preparation for curing neurosis. In order to solve the problems of difficult control of pathogenetic condition, generation of side effect, adverse reaction, etc. by using the present usually used tranquilizing and anti-ademosyne neurosis medicine for treating neurosis, a preparation is prepared by a traditional Chinese medicine prescription of common anemarrhena rhizome, polygala root, gastrodia elata, tall gastrodia tuber, longan aril, caulis polygoni multiflori, jujube seed, barbary wolfberry fruit and cornel as main medicine according to a certain content. The combination of medicine for treating neurosis can obtain the purposes of tonifying of the kidney, benefiting of essence and blood, permanent cure with coursing the liver and rectifying the spleen for temporary solution. The present invention has the prominent advantages of enriching but not slimy, tonifying without dryness, clearing without cold, regulation of yin and yang, tonifying of weakness, discharge of solid, reliable curative effect, no obvious side effect, etc. The effective rate for treating internal medicine patients with neurosis can reach 98.3% through trial.
The invention discloses a C-glycosylflavones composition. The composition is extracted from plants of genus Trollius, and mainly contains orientin, vitexin, or vitexin esters and orientin esters. The invention also discloses a preparation method of the C-glycosylflavones composition. The preparation method is characterized by comprising extracting Trollius Chinensis Bge., performing macroporous resin column chromatography, and performing selective gradient elution with ethanol-water mixed solvent. The macroporous resin is preferably weak polarity macroporous resin. The C-glycosylflavones composition has pharmacological effects in resisting oxidation and inflammation, and inhibiting bacterial infection; and can be applied as ingredient of drugs and functional foods.
In both rats and dogs, nephropathy has been associated with intravenous (bolus and infusion) administration of pamidronate disodium.

Two 7 day intravenous infusion studies were conducted in the dog wherein pamidronate disodium was given for 1, 4, or 24 hours at doses of 1 to 20 mg/kg for up to 7 days. In the first study, the compound was well tolerated at 3 mg/kg (1.7 x highest recommended human dose [HRHD] for a single intravenous infusion) when administered for 4 or 24 hours, but renal findings such as elevated BUN and creatinine levels and renal tubular necrosis occurred when 3 mg/kg was infused for 1 hour and at doses of ≥10 mg/kg. In the second study, slight renal tubular necrosis was observed in 1 male at 1 mg/kg when infused for 4 hours. Additional findings included elevated BUN levels in several treated animals and renal tubular dilation and/or inflammation at ≥1 mg/kg after each infusion time.

Pamidronate disodium was given to rats at doses of 2, 6, and 20 mg/kg and to dogs at doses of 2, 4, 6, and 20 mg/kg as a 1 hour infusion, once a week, for 3 months followed by a 1 month recovery period. In rats, nephrotoxicity was observed at ≥6 mg/kg and included increased BUN and creatinine levels and tubular degeneration and necrosis. These findings were still present at 20 mg/kg at the end of the recovery period. In dogs, moribundity/death and renal toxicity occurred at 20 mg/kg as did kidney findings of elevated BUN and creatinine levels at ≥6 mg/kg and renal tubular degeneration at ≥4 mg/kg. The kidney changes were partially reversible at 6 mg/kg. In both studies, the dose level that produced no adverse renal effects was considered to be 2 mg/kg (1.1 x HRHD for a single intravenous infusion).
Apparatus and methods for loading, transporting and dumping a plurality of containers on a vehicle are provided. The apparatus includes a frame pivotally attachable a vehicle bed, an upper container engaging means and a lower container engaging means, both coupled to the frame. The upper container engaging means is moveable between a first height and a second height, the first height and the second height differing by greater than at least the height of a container. The lower container engaging means may be stowed and deployed. The upper container engaging means is moveable to the first height for loading a first container when the lower container engaging means is stowed. The lower container engaging means is deployed at the first height for loading the second container when the upper container engaging means is at the second height. The first container and second container may thereby be sequentially loaded and simultaneously transported on the vehicle.
Up to 12 patients will be treated with IT injection of VG161 ar dose level of 1.0x10E8 PFU x 3 days. and Nivolumab per approved label.
Fusobacterium nucleatum (Fn), as a conditional pathogen, can cause a range of oral and gastrointestinal diseases. However, existing clinical detection methods require expensive equipment and complex procedures, which are inconvenient for large-scale screening in epidemiological research. The purpose of this study was to establish a reliable, rapid, and inexpensive detection method based on CRISPR/Cas12a technology for the detection of Fn. Specific recombinase polymerase amplification (RPA) primer sequences and crRNA sequences were designed based on the nusG gene of Fn. Subsequently, a fluorescence assay and a lateral flow immunoassay were established using the RPA and CRISPR-Cas12a system (RPA-CRISPR-Cas12a). Sensitivity validation revealed a limit of detection of 5 copies/µL. This method could distinguish Fn from other pathogens with excellent specificity. Furthermore, the RPA-CRISPR-Cas12a assay was highly consistent with the classical quantitative real-time PCR method when testing periodontal pocket samples. This makes it a promising method for the detection of Fn and has the potential to play an increasingly important role in infectious disease testing.IMPORTANCEFusobacterium nucleatum (Fn) naturally exists in the microbial communities of the oral and gastrointestinal tracts of healthy individuals and can cause inflammatory diseases in the oral and gastrointestinal tracts. Recent studies have shown that Fn is closely associated with the occurrence and development of gastrointestinal cancer. Therefore, the detection of Fn is very important. Unlike the existing clinical detection methods, this study established a fluorescence-based assay and lateral flow immunoassay based on the RPA and CRISPR-Cas12a system (RPA-CRISPR-Cas12a), which is fast, reliable, and inexpensive and can complete the detection within 30-40 minutes. This makes it a promising method for the detection of Fn and has the potential to play an increasingly important role in infectious disease testing.
Human Immunodeficiency virus causes depletion of CD 4  cells. The depletion of CD 4  cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD 4  count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides immunomodulator based on Mycobacterium w. Its use in associated with symptomatic improvement as well as improvement in immunity as evidenced by improved CD 4  count in HIV infected individuals.
BACKGROUND: Dysbiosis of the gut microbiome is frequent in the intensive care unit (ICU), potentially leading to a heightened risk of nosocomial infections. Enhancing the gut microbiome has been proposed as a strategic approach to mitigate potential adverse outcomes. While prior research on select probiotic supplements has not successfully shown to improve gut microbial diversity, fermented foods offer a promising alternative. In this open-label phase I safety and feasibility study, we examined the safety and feasibility of kefir as an initial step towards utilizing fermented foods to mitigate gut dysbiosis in critically ill patients.
METHODS: We administered kefir in escalating doses (60 mL, followed by 120 mL after 12 h, then 240 mL daily) to 54 critically ill patients with an intact gastrointestinal tract. To evaluate kefir's safety, we monitored for gastrointestinal symptoms. Feasibility was determined by whether patients received a minimum of 75% of their assigned kefir doses. To assess changes in the gut microbiome composition following kefir administration, we collected two stool samples from 13 patients: one within 72 h of admission to the ICU and another at least 72 h after the first stool sample.
RESULTS: After administering kefir, none of the 54 critically ill patients exhibited signs of kefir-related bacteremia. No side effects like bloating, vomiting, or aspiration were noted, except for diarrhea in two patients concurrently on laxatives. Out of the 393 kefir doses prescribed for all participants, 359 (91%) were successfully administered. We were able to collect an initial stool sample from 29 (54%) patients and a follow-up sample from 13 (24%) patients. Analysis of the 26 paired samples revealed no increase in gut microbial α-diversity between the two timepoints. However, there was a significant improvement in the Gut Microbiome Wellness Index (GMWI) by the second timepoint (P = 0.034, one-sided Wilcoxon signed-rank test); this finding supports our hypothesis that kefir administration can improve gut health in critically ill patients. Additionally, the known microbial species in kefir were found to exhibit varying levels of engraftment in patients' guts.
CONCLUSIONS: Providing kefir to critically ill individuals is safe and feasible. Our findings warrant a larger evaluation of kefir's safety, tolerability, and impact on gut microbiome dysbiosis in patients admitted to the ICU.
TRIAL REGISTRATION: NCT05416814; trial registered on June 13, 2022.
PURPOSE: Provided is an anti-Fas antibody having cross reactivity between Fas of mouse and human, and having apoptosis inducing activity to protect normal cell and induce apoptosis of abnormal cell, which is useful for prevention and treatment of diseases originated from aberration of Fas/Fas ligand system. CONSTITUTION: Extra cellular regions of human Fas and murine IL-3R are truncated and introduced into expression vector to produce recombinant protein used for Fas antigen, which is purified from transfected COS-1 cells. Fas knockout mouse is immunized with Fas antigen. Cell fusion between myeloma cell line, P3-U1, and spleen cell of immunized mouse is carried out. High titer hybridoma cell is selected using 8-azaguanine resistance marker. Each hybridoma cell is cloned and cDNA library is constructed for each clones. cDNA for antibody gene is screened and corresponding epitope of Fas antigen is determined. Gene for humanized anti Fas antibody is constructed by PCR and recombinant DNA manipulation and expressed from transfected cells. Purified humanized anti Fas antibody can be used to treat diseases such as autoimmune diseases, arthrosclerosis, kidney diseases, allergy, hepatitis and AIDS.
Work by many groups demonstrate links between peripheral markers of inflammation and symptoms of depression. Here, Nusslock and colleagues present an update to their neuroimmune network model to incorporate a developmental lens. They propose that specific neural circuits may be responsible for causing heightened inflammation. One principal circuit includes the amygdala and prefrontal cortex and is proposed to be involved in threat detection. Thus, heightened threat sensitivity resulting from early life stress is suggested to cause increases in inflammatory signaling. Second, the authors suggest that reward circuits, including the striatum, may be targets of increased inflammation leading to symptoms of anhedonia. In this commentary, I add context to the model proposed by Nusslock et al., suggesting that taking a learning perspective and considering additional circuits, including the hippocampus and midline structures may be necessary to more fully account for the phenomena described by the authors.
Novel systems, methods, and devices for implementing prescription delivery and for providing medication reminders are provided. One system for providing a prescription medication delivery service operates by directly submitting a prescription delivery request to the prescription medication delivery service. A server may receive a requesting delivery signal related to a prescription medication via a communication network. A physician device may receive input relating to a selection of a prescription delivery option within a pharmacy dispensing system and transmit a corresponding message via the communication network. A prescription delivery service server may receive the message and coordinate delivery of the prescription medication based at least in part upon the message. An electronic device may obtain a confirmation indication when the prescription medication is delivered and transmit a confirmation of completed delivery.